similar staining patterns (Extended Data Fig. 2a ). Notch pathway ligands, receptors, and targets were also expressed in human SCLC cell lines 15 and tumours (Extended Data Fig. 2b) . Treatment with the γ -secretase inhibitor dibenzazepine (DBZ) 16 led to the accumulation of the inactive form of Notch and decreased GFP, Hes1 and Nrarp expression in TKO Hes1 GFP/+ tumours ( Fig. 1g and Extended Data Fig. 2c -g). GFP high SCLC cells grown without the Notch ligand Dll4 showed decreased expression of GFP, Hes1, and the transcriptionally active Notch1 intracellular domain (N1ICD) ( Fig. 1h and Extended Data Fig. 2h , i). Thus, a significant fraction of SCLC cells activate endogenous Notch signalling.
Consistent with the inhibition of NE differentiation by Notch during development [4] [5] [6] , GFP high cells expressed lower levels of NE genes relative to GFP neg cells in TKO Hes1 GFP/+ tumours ( Fig. 1i and Extended Data Fig. 2j-l) . Non-NE SCLC cells marked by high expression of CD44 and mesenchymal markers (for example, vimentin) were previously described 17 , but the majority of GFP high cells expressed the epithelial marker EpCam, had no detectable CD44 on their surface, and did not upregulate vimentin (Extended Data Fig. 2m , n), indicating that GFP high and CD44 high cell populations within primary TKO tumours are largely distinct. Cell lines of GFP neg cells grew as floating clusters typical of NE SCLC while GFP high cells grew adherently, further suggestive of a change in differentiation ( Fig. 1j ). Microarray gene expression analysis of GFP high and GFP neg cells (Extended Data Fig. 3a, b and Supplementary Table 1 ) supported an enrichment for Notch pathway activation (Extended Data Fig. 3c and Supplementary  Table 2 ) and a suppression of neuroendocrine/neuronal differentiation in GFP high cells (Extended Data Fig. 3d-h and Supplementary  Tables 3 and 4 ). GFP high cells were also less proliferative than GFP neg cells and formed slower-growing tumours ( Fig. 1k and Extended Data Fig. 4a-d) . Thus, the phenotypes of TKO SCLC cells with endogenous Notch activity are consistent with the tumour-suppressive effects of ectopic Notch activation in SCLC 8 .
On the basis of cell cycle and cell death analyses ( Fig. 1k and Extended Data Fig. 5a ), GFP neg cells should rapidly outcompete GFP high cells in tumours (Extended Data Fig. 5b ), which is inconsistent with the observed ratio of approximately three GFP neg cells to one GFP high cell ( Fig. 1e ) and the similar frequencies of Hes1 pos cells in early-and late-stage TKO tumours (Extended Data Fig. 1a ). Tumours initiated by expressing Cre from the NE-specific CGRP promoter 18 contained Hes1 pos cells (Extended Data Fig. 5c-e ), indicating that both non-NE Hes1 pos and NE Hes1 neg cells can arise from an NE cell of origin. In the analysis of TKO tumour cells by single-cell quantitative PCR with reverse transcription (qRT-PCR), all non-NE Hes1 pos cells expressed at least one Notch receptor and all NE Hes1 neg cells expressed at least one Notch ligand. However, a fraction of NE Hes1 neg SCLC cells also expressed at least one receptor ( Fig. 2a ), suggesting that these cells may be responsive to Notch ligands. Indeed, stimulation of GFP neg tumour cells with a high-affinity form of Dll4 (ref. 19 ) induced GFP expression and non-NE phenotypes in ~ 50% of cells (Fig. 2b, c and Extended Data Fig. 5f ). Isolation and re-plating of the cells that remained GFP neg on Dll4-coated plates showed that a subset could again be induced to express GFP (Extended Data Fig. 5g, h) , suggestive of a cyclic or Figure 1 | SCLC tumours contain slow-growing, Notch-active non-neuroendocrine tumour cells. a, b, Representative Hes1 immunohistochemistry (IHC) (a) and frequency of Hes1 pos cells (b) in mouse SCLC (n = 5 mice, 83 tumours). c, d, As in a, b, for human SCLC (n = 172 sections). e, Flow cytometry analysis showing the percentage of GFP high cells from pooled TKO Hes1 GFP/+ tumours (n = 18 mice). f, qRT-PCR of Notch pathway genes in GFP high relative to GFP neg tumour cells (n = 3 mice). g, As in e, with mice treated with dimethylsulfoxide (DMSO) (n = 5 mice) or DBZ (n = 4 mice). h, Immunoblots of GFP high cell lines grown with Dll4 or 72 h after removal from Dll4. i, GFP and Uchl1 (NE marker) immunofluorescence in TKO Hes1 GFP/+ tumours (representative of n = 3 biological replicates). j, Images of cell cultures established from GFP neg and GFP high tumour cells (representative of n = 5 biological replicates). Inset: NE KP1 SCLC cell line. k, EdU incorporation in cells sorted from TKO Hes1 GFP/+ tumours (n = 3 mice). *P < 0.05; **P < 0.01; ***P < 0.001. Two-tailed paired (f, k) or unpaired (g) Student's t-test. Data are mean ± s.d. Scale bars, 50 μ m. stochastic expression of Notch receptors on NE SCLC cells. Dll4 effects on GFP neg cells were suppressed by DBZ and the Notch2/3-blocking antibody tarextumab 20 ( Fig. 2d and Extended Data Fig. 5i ). Cells that express both Notch ligands and receptors are also present in human SCLC cell lines, and Dll4 induced HES1 in these lines (Extended Data Fig. 5j , k). Although GFP expression in GFP high cell lines depended on exogenous Dll4 ( Fig. 1h and Extended Data Fig. 2h , i), this dependence was partly rescued by co-culture with NE cell lines and the rescue was blocked by DBZ ( Fig. 2e and Extended Data Fig. 5l , m), indicating that NE SCLC cells can provide Notch ligands to SCLC cells expressing Notch receptors. Thus, a subset of NE SCLC cells express levels of Notch that may be sufficient for signalling induction by ligands on neighbouring cells, contributing to their transition towards a non-NE fate.
After establishment of the non-NE state, however, we observed no reversal to an NE state upon Notch pathway silencing ( Fig. 2f and Extended Data Fig. 5n -p). SCLC cells with intermediate levels of GFP expression (GFP int cells) displayed intermediate activation of the Notch pathway, as expected, but clustered mostly with GFP neg cells and away from GFP high cells (Extended Data Fig. 6a-e ). Thus, a certain threshold (strength and/or duration) of Notch pathway activation may be required to convert NE SCLC cells to the non-NE state. Nevertheless, some GFP int tumour cells were already in the process of switching to the non-NE state, as some adherent non-NE cells were formed from GFP int cells in culture (Extended Data Fig. 6f ). These observations are reminiscent of some irreversible fate switches induced by Notch 1,21 , although we cannot exclude the possibility that some non-NE SCLC cells might retain the ability to revert to an NE state in specific contexts.
In SCLC cell lines, constitutive Notch activation results in a loss of NE differentiation after an initial growth suppressive phase 8 (Extended Data Fig. 7a, b ). N1ICD inhibited Ascl1 expression (Extended Data Fig. 7b and refs 8, 22) but Ascl1 knockdown by itself did not significantly change the expression of NE genes and cellular morphology (Extended Data Fig. 7c-e ), suggesting that Ascl1 inhibition by Notch in SCLC cells is insufficient for the NE to non-NE switch. Analysis of microarray data ( Supplementary Table 1 ) identified Rest/Nrsf as a candidate transcription factor that may repress genes expressed at lower levels in Notch-active, non-NE GFP high cells relative to NE GFP neg cells ( Fig. 3a ). Rest is a transcriptional repressor typically expressed in non-neuronal tissues where it suppresses the expression of neuronal genes 23,24 . Rest expression is higher in GFP high cells relative to GFP neg cells and is induced after Dll4 stimulation of GFP neg cells ( Fig. 3b and Extended Data Fig. 7f, g) . Rest is also a direct target of N1ICD ( Fig. 3c, d) . Rest downregulation did not affect the expression of NE genes (Extended Data Fig. 7h , i) but reduced the ability of N1ICD to induce an NE to non-NE transition in SCLC cells ( Fig. 3e and Extended Data Fig. 7j , k). Rest bound to the promoters of NE genes ( Fig. 3f ) and its overexpression in NE SCLC cells was sufficient to downregulate the expression of NE genes and convert these cells to a non-NE phenotype (Fig. 3g , h and Extended Data Fig. 7l ). Thus, induction of Rest is a critical step by which the Notch pathway inhibits NE differentiation in SCLC. Epigenetic remodelling involving repressor complexes containing Rest (reviewed in ref. 25) may contribute to the irreversibility of the Notch-driven NE to non-NE switch in SCLC cells.
Gene expression profiles suggested that non-NE Hes1 pos SCLC cells might be involved in extracellular matrix organization and regulation of cell adhesion (Extended Data Fig. 3g ), reminiscent of tumour-stroma interactions in other cancers 26 . Furthermore, GFP high and GFP neg cells resembled astroglial cells and neurons, respectively (Extended Data Fig. 8a ), and astroglial cells can provide trophic support for neurons 27 . Therefore, non-NE tumour cells might act as a tumourderived microenvironment and contribute to SCLC development through non-cell-autonomous effects on NE tumour cells. In a three-dimensional culture, bulk TKO Hes1 GFP/+ tumour cells grew better than GFP high or GFP neg cells alone ( Fig. 4a and Extended Data Fig. 8b-d ). Co-culture with non-NE GFP high cell lines or with conditioned medium from GFP high cells promoted the growth of NE SCLC cell lines ( Table 1 ) and biological features (for example, known role in neural/NE growth), only one showed a significant growth-promoting effect (Extended Data Fig. 8p, q) , suggesting that factors not tested are implicated and/or that multiple factors act in concert to stimulate NE SCLC cell growth. Interestingly, however, the factor that promoted the growth of NE SCLC cells was midkine, which is secreted by glial cells to promote neuronal growth 28 . We detected midkine in the supernatant of GFP high SCLC cells (Extended Data Fig. 8r ) and in the serum of patients with SCLC (Extended Data Fig. 8s ), suggesting that human tumours also produce midkine. The growth advantages provided by GFP high cells were not affected by Notch inhibition in co-culture assays (Extended Data Fig. 8t ), indicating that the tumour-promoting effects of non-NE tumour cells are due to the differentiation state triggered by Notch activity, and not to ongoing Notch signalling. A major factor in the dismal survival rates for SCLC is rapid relapse following standard-of-care chemotherapy (often cisplatin or carboplatin with etoposide) 7 . GFP high tumour cell lines survived better than GFP neg tumour cell lines in response to cisplatin and etoposide (Extended Data Fig. 9a, b ). Acute treatment of TKO mice with cisplatin and etoposide increased the number of cleaved caspase-3-positive (CC3 pos ) apoptotic tumour cells (Extended Data Fig. 9c ), which correlated with an increase in the frequency of Hes1 pos cells (Extended Data Fig. 9d ); most of the CC3 pos cells were (Hes1)GFP neg cells in these experiments ( Fig. 4f and Extended Data Fig. 9e ). The frequency of Hes1 pos SCLC cells was also higher in mice treated with a longer-term chemotherapy protocol (Extended Data Fig. 9f ), suggesting that these cells might play a role in chemo-response. In a cohort of patients with SCLC, we found a trend for HES1 positivity in tumours as a negative prognostic factor for overall and progression-free survival (Extended Data Fig. 9g -l and Supplementary Table 5 ). In an SCLC allograft model (Extended Data Fig. 10a, b ), a combination of the Notch2/3 antagonist tarextumab and combined carboplatin and irinotecan (hereafter carboplatin/ irinotecan) achieved greater tumour inhibition than tarextumab or carboplatin/irinotecan alone ( Fig. 4g and Extended Data Fig. 10c ), despite relatively low numbers of Hes1 pos cells in this specific model ( Fig. 4h and Extended Data Fig. 10d, e ). We observed similar effects in a patient-derived xenograft model, OMP-LU66 ( Fig. 4i ). Importantly, tarextumab treatment delayed the acquisition of chemoresistance and relapse during chemotherapy in these models ( Fig. 4g , i). These effects were generally accompanied by decreased proliferation in non-NE Hes1 pos cells and increased apoptosis in NE Ascl1 pos cells (Extended Data Fig. 10f -m), as well as a reduction in Hes1 pos cells ( Fig. 4h and Extended Data Fig. 10d -e, n-o). Thus, tarextumab treatment can block the generation of non-NE Hes1 pos cells and limit their proliferation during tumour development. In combination with chemotherapy, tarextumab treatment can also affect the survival and possibly the proliferation of NE tumour cells.
SCLC tumours, which have few infiltrating stromal cells 8 , can make their own diverse microenvironment 17,29 . Here we show that activation of Notch signalling during SCLC progression generates an unexpected level of intratumoural heterogeneity. The amount (duration and strength) of Notch signalling required for the NE to non-NE fate switch is unknown, but a threshold is probably required on the basis of analysis of GFP int cells. Furthermore, although Notch1 is also expressed and active in SCLC, blockade of just Notch2/3 was sufficient to suppress tumour growth and the generation of non-NE cells. Notch activation is likely to be regulated at multiple levels in SCLC. First, our ex vivo data indicate that ligands expressed on neighbouring NE SCLC cells are sufficient to maintain Notch signalling in non-NE cells, but may not be sufficient for the generation of new non-NE cells. In primary tumours, Notch activation could be enhanced by signals from the lung microenvironment, as liver metastases (Extended Data Fig. 1a ) and subcutaneous allografts grown from Hes1 neg /GFP neg cells (Extended Data Fig. 4d ) contained fewer Hes1 pos /GFP pos cells than primary tumours. The initial generation of non-NE SCLC cells may also promote the generation of more Notch-activated cells via unknown mechanisms. Second, although most of the loss-of-function NOTCH mutations in human SCLC tumours are heterozygous 8 , they might be sufficient to lower signalling from Notch receptors in NE SCLC cells and impair the NE to non-NE switch in response to ligands.
Notch signalling can be both tumour suppressive (intrinsically to NE cells) and pro-tumorigenic (through the generation of non-NE cells that are more chemoresistant and can promote NE cell growth) in SCLC. Our data provide a rationale for combining chemotherapy and Notch inhibition as a therapy for patients with SCLC whose tumours contain Notch-active tumour cells (Fig. 4j ); expression of HES1 or other Notch targets in tumour biopsies, or even detection in the serum of patients of factors secreted by Notch-active SCLC cells (for example, midkine), may serve as biomarkers for this personalized therapy. While tarextumab treatment showed a trend towards an improvement in overall and progression-free survival in patients with extensive-stage SCLC whose tumours expressed elevated levels of Notch target genes, including HES1, in a phase 1b clinical trial (identifier NCT01859741); the same effect was not observed in a larger cohort of patients in a phase 2 study (unpublished data). It is possible that combination therapy with Notch inhibitors might be more beneficial to early-stage SCLC patients or as a second-line therapy following chemotherapy. In contrast, relapsed late-stage tumours with fast-growing NE tumour cells might be inhibited by acute activation of the Notch pathway. The dual role of Notch signalling in SCLC illustrates the complex functions of developmental pathways in cancer and should guide the development of novel therapeutic approaches.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Tumours were collected for analysis after around 5-7 months for Ad-CMV-Cre or 7-8 months for Ad-CGRP-Cre, unless otherwise stated. In accordance with our animal protocol, mice were euthanized when they showed difficulty breathing, regardless of time point. DBZ injections. TKO Hes1 GFP/+ mice were treated with the γ -secretase inhibitor DBZ (Selleckchem, S2711) as previously described 33 . Mice were randomized and injected intraperitoneally once per day with 30 μ mol per kg (body weight) of DBZ (or DMSO control) for 5 days, and tumours were collected on day 6 for flow cytometry or fixed for histological analyses. Chemotherapy treatments in TKO mice. TKO or TKO Hes1 GFP/+ mice bearing tumours were randomized for treatment. For acute responses, mice were treated with cisplatin (7.5 mg per kg (body weight), Teva) on day 1, and a combination of cisplatin and etoposide (15 mg per kg (body weight), Novaplus) on days 2 and 4. Lungs were fixed for histological analyses a few hours after the last injection. For longer-term chemotherapy experiments, as we observed high toxicity with etoposide administration, TKO Rosa26 LSL-luciferase mice were treated weekly for 3 weeks with saline or 5 mg per kg (body weight) cisplatin only. Subcutaneous tumour implantation. For subcutaneous tumour growth of GFP neg or GFP high cells, 2,000 cells were FACS-sorted and implanted subcutaneously on the lower left and right quadrants of 8-to 10-week-old immunocompromised NOD. Cg-Prkdc scid IL2rg tm1Wjl /SzJ (NSG) mice (no selection for sex of mice). Mice were euthanized and tumours were collected after approximately 2 months. The tumours did not exceed the 1.75 cm diameter limit permitted by our animal protocol.
For the human patient-derived xenograft and TKO allograft tumour growth models, NOD.CB17-Prkdc scid /NcrCrl (NOD/SCID, Charles River Laboratories) mice were maintained under pathogen-free conditions and provided with sterile food and water ad libitum. Patient-derived xenograft models were established from patient biopsies provided by Molecular Response (San Diego, California, USA). OMP-LU66 was established at OncoMed Pharmaceuticals. For the subcutaneous xenograft studies, 100,000 OMP-LU66 cells in 100 μ l 50% Matrigel (BD Biosciences)/50% Hank's balanced salt solution supplemented with 2% heat-inactivated fetal bovine serum and 20 mM HEPES (Life Technologies) were implanted into the left flank region of 7-to 8-week-old NOD/SCID mice (no selection for sex of mice) with a 25-gauge needle. Phage display selection and screening for tarextumab 20 . Using a human Fab phage display library (HuCAL GOLD, MorphoSys AG 34 ), functional anti-Notch antibodies were discovered from selections against recombinant Notch2 extracellular domain (EGF1-12) containing the ligand-binding site. Tarextumab treatments. NOD/SCID mice implanted with OMP-LU66 or TKO allografts were randomized and treated with a control antibody or tarextumab (OMP-59R5, 40 mg per kg (body weight), once every 2 weeks) as a single agent or in combination with the chemotherapy agents carboplatin (25 mg per kg (body weight), once-weekly, Teva) and irinotecan (25 mg per kg (body weight), onceweekly, Pfizer). We used carboplatin and irinotecan (instead of cisplatin and etoposide) for these longer-term studies as they are less toxic, better tolerated by the mice, and have been shown to have similar efficacies as cisplatin and etoposide 35, 36 . To avoid the side effects of total Notch pathway inhibition in vivo 37, 38 , we sought to reduce Notch signalling with the Notch2/3 antagonist tarextumab. After approximately four cycles, chemotherapy was discontinued and tarextumab dosing was continued until study completion. Mice with tumour volumes at or exceeding the 2,500 mm 3 limit permitted by the Institutional Animal Care and Use Committee were euthanized regardless of time point.
Preparation of single-cell suspensions from SCLC tumours for flow cytometry.
Tumours were dissected from the lungs of TKO Hes1 GFP/+ mice approximately 5-7 months after tumour induction and digested as previously described 39 . The antibodies used were CD45-PE-Cy7 (eBioscience, clone 30-F11, 1:100), CD31-PE-Cy7 (eBioscience, clone 390, 1:100), TER-119-PE-Cy7 (eBioscience, clone TER-119, 1:100), CD24-APC (eBioscience, clone M1/69, 1:200), Ncam1 (Cedarlane, clone H28-123-16, 1:100), anti-rat-IgG2a-PE (eBioscience, clone r2a-21B2, 1:200), EpCam (eBioscience, clone G8.8, 1:100), and CD44-APC-Cy7 (BioLegend, clone IM7, 1:100). 7-Aminoactinomycin D (1 μ g ml -1 ; Invitrogen) or DAPI was used to label dead cells. Flow cytometry and sorting of SCLC tumour cells. FACS was performed using a 100 μ m nozzle on a BD FACSAria II using FACSDiva software. The sequential gating strategy is outlined in Extended Data Fig. 1d . Fluorophore compensation was performed for each experiment using either unstained cells or BD CompBeads (BD Biosciences) stained with individual fluorophore-conjugated antibodies, and compensation was calculated by FACSDiva. Data were analysed using FlowJo software and gates were set on the basis of unstained samples. EdU analysis in vivo. TKO Hes1 GFP/+ mice were injected intraperitoneally with 100 mg per kg (body weight) EdU (5-ethynyl-2′ -deoxyuridine; Life Technologies) 8 h before euthanasia. GFP neg and GFP high tumour cells were sorted by FACS before being fixed and subject to EdU staining using the Click-iT Plus EdU Pacific Blue flow cytometry assay kit (Life Technologies). Propidium iodide was used to stain for total DNA content and percentage EdU incorporation of GFP neg and GFP high cells was analysed using a BD FACSAria II. Purification of soluble Dll4 ligand. The extracellular domain of rat Dll4 containing affinity-enhancing G28S, F107L, L206P N118I, I143F, H194Y, and K215E mutations (named Dll4 E12 or Dll4 in the manuscript) was cloned into the pAcGp67A vector and modified with a carboxy (C)-terminal 8× His tag 19 . Dll4 E12 was expressed using baculovirus by infecting 1 l of Hi-Five cells (Invitrogen) from Trichoplusia ni at a density of 2 × 10 6 cells per millilitre and harvesting cultures after 72 h. The cultures were centrifuged to remove the cells, and proteins were purified from supernatants by nickel and size-exclusion chromatography. Plasmids. The MigR1-ires-GFP (Ctrl) and MigR1-N1ICD-ires-GFP retroviral vectors were gifts from W. S. Pear (University of Pennsylvania, Philadelphia). For doxycycline-inducible expression, we cloned N1ICD into the pLIX-403 vector (a gift from D. Root, Addgene 41395). For Rest overexpression, we cloned the Nrsf(Rest) fragment from pHR′ -NRSF-CITE-GFP (a gift from J. Nadeau, Addgene 21310 (ref. 40)) into the MigR1-ires-GFP or pLIX-403 vectors. Ascl1 (1: CTCCAACGACTTGAACTCTAT; 2: CCACGGTCTTTGCTTCTGTTT) and Rest (1: GTGTAATCTACAATACCATTT; 2: CCCAAGACAAAGACAAGTAAA) short hairpin RNAs (shRNAs) were obtained from the MISSION shRNA library (Sigma-Aldrich). Guide RNA (sgRNA) against Rest (CATCATCTGCACGTACACGA) was designed using the sgRNA Designer (Broad Institute) and cloned into the lentiCRISPR v2 backbone (a gift from F. Zhang, Addgene 52961 (ref. 41)). Cell lines and cell culture assays. Except for 293T cells that were grown in DMEM, all cell lines were grown in RPMI-1640 medium supplemented with 10% bovine growth serum (BGS) (Fisher Scientific) and penicillin-streptomycin-glutamine (Gibco). Mouse KP1, KP2, and KP3 and human NJH29 SCLC cell lines were generated in the laboratory and have been described 8, 32, 42 . GFP neg and GFP high cell lines were isolated by FACS from individual mice. Human NCI-H82 and NCI-H889 cells were purchased from the American Type Culture Collection and authenticated by STR analysis. All cell lines tested negative for mycoplasma.
Transfections, viral infections, and CRISPR knockout validation.
Transfections and viral infections were performed as previously described 39 . For acute analysis of gene expression changes, RNA was isolated from GFP high cells FACS-sorted 48 h after transfection with MigR1-N1ICD or Rest-IRES-GFP or the empty vector control. Viral transductions of N1ICD or Rest were used to generate adherent non-NE cells from NE cells, a process taking about 1-2 weeks. The cells were then expanded and collected for immunoblot analyses. For isolation of Rest knockout clones, sgRNA-infected cells were selected with puromycin (2 μ g ml -1 ) for 4 days and single cells were sorted into individual wells in 96-well plates by FACS. After 2 weeks, clones were picked and those with biallelic frameshift mutations resulting in premature truncation of the translated protein were verified by TOPO PCR cloning (Thermo Fisher Scientific) and Sanger sequencing. Dll4 ligand assays. Tissue culture plates were coated overnight with 200 nM of purified Dll4 in PBS at 4 °C, then washed twice with PBS to remove any unbound ligand before seeding of cells. GFP high cell lines were maintained on Dll4-coated dishes. To assay for acute responses to the lost of Notch activation, cells were kept on Dll4-coated plates or seeded on plates without Dll4 and collected 72 h later Letter reSeArCH for analyses. GFP neg cell lines were maintained on non-Dll4-coated dishes unless otherwise indicated.
To test for Notch ligands expressed by NE SCLC cells, mCherry-labelled NE (KP1 and KP3) cells were co-cultured with GFP high cell lines at a 3:1 ratio with 10 μ M DBZ or DMSO control without exogenous Dll4. This ratio was based on the average number of GFP neg and GFP high cells in TKO Hes1 GFP/+ tumours (27.7% GFP high cells ≈ 3:1 ratio). Median GFP fluorescence intensity of mCherry-negative, GFP high cells was quantified by flow cytometry after 72 h.
For Dll4 stimulation of human cell lines (suspension), plates were coated overnight with 400 nM Dll4 in PBS at 4 °C. Plates were washed twice with PBS, coated with 0.01% poly-d-lysine (Sigma-Aldrich) for an hour at 37 °C and then washed twice with PBS before seeding of cells.
For GFP neg ex vivo assays, DBZ was added at a concentration of 10 μ M and tarextumab at 100 μ g ml -1 . Cells were analysed after 2 weeks by flow cytometry for the generation of GFP high cells.
Matrigel growth assay. Fifty thousand GFP neg , GFP high or bulk tumour cells (mixture of GFP neg and GFP high ) were sorted from TKO Hes1 GFP/+ tumours, resuspended in 100 μ l of modified DMEM/F12 medium containing 50% Matrigel as previously described 43 and then layered with 200 μ l of medium. Overall survival was assayed 1 week later by incubating with AlamarBlue (Thermo Fisher Scientific) for 4 h. Supernatant was removed and fluorescence of the Matrigel layer was read by a fluorescence plate reader (excitation 560 nm, emission 590 nm). For immunostaining, the Matrigel layer was fixed overnight with 10% formalin in PBS then washed twice with PBS before being embedded in histogel and subjected to processing for paraffin embedding. Co-culture and conditioned medium assays. For co-culture cell growth assays, NE mouse SCLC cells (KP1, KP2) were labelled with firefly luciferase and enhanced GFP by lentiviral infection. These cells were then mixed with GFP high cells at a 3:1 ratio (12,000 NE cells + 4,000 GFP high cells) in 96-well white bottom plates. Luciferase activity was assayed 72 h later by the Steady-Glo luciferase assay system (Promega) according to the manufacturer's protocol. For conditioned medium assays, 0.5 × 10 6 GFP high cells were seeded overnight in 6-cm dishes. The medium was then changed and conditioned medium collected after 24 h. Twelve thousand NE cells per well of a 96-well plate were resuspended in conditioned medium and luciferase activity was assayed 72 h later. Conditioned medium from NE cells was used as the control, although in preliminary experiments we did not notice any difference in luciferase activity between NE-conditioned medium and regular medium.
For co-culture EdU assays, unlabelled KP1 and KP2 were co-cultured with GFP high cells at a 3:1 ratio (150,000 NE cells + 50,000 GFP high cells) in 12-well plates for 72 h and then incubated with 10 μ M EdU (Life Technologies) for 3 h. Both floating and adherent populations were collected and subject to EdU staining using a Click-iT Plus EdU Pacific Blue flow cytometry assay kit (Life Technologies). Cisplatin and etoposide treatments. Twenty thousand NE or 4,000 GFP high cells were seeded per well of a 96-well plate in RPMI medium with 2% BGS. One microlitre of drug solution was added per well the next day at the appropriate concentration and cell viability was assayed 48 h later by the MTT assay (Roche). Growth assay with recombinant proteins. Twenty thousand NE cells were seeded per well of a 96-well plate in RPMI medium with 2% BGS in the presence of the recombinant proteins. Cell viability was assayed after 72 h by the AlamarBlue assay. The following recombinant proteins were used: Midkine (OriGene TP723299, 50 ng ml -1 ), Betacellulin (BioLegend 551302, 5 ng ml -1 ), Gdf15 (MyBioSource MBS205834, 25 ng ml -1 ), Bmp4 (BioLegend 595301, 50 ng ml -1 ), Ephrin A1 (BioLegend 755002, 50 ng ml -1 ), SCF (BioLegend 579702, 50 ng ml -1 ), and Fstl1 (R&D Systems 1738-FN-050, 200 ng ml -1 ). Midkine ELISA assay. One and a half million NE cells or 0.5 × 10 6 GFP high cells were seeded per well of a 12-well plate in RPMI medium with 2% BGS. Supernatant was collected after 24 h, centrifuged at 1,500 r.p.m. for 10 min and assessed for the presence of midkine by an ELISA (LifeSpan Biosciences, LS-F5765) according to the manufacturer's instructions. Data were analysed using http://www.elisaanalysis.com/. Immunostaining. Tissues were fixed overnight with 10% formalin in PBS before processing for paraffin embedding. For IHC, paraffin sections were stained as previously described 8 . In brief, a citrate-based solution (Vector Laboratories) was used for antigen retrieval. DAB (Vector Laboratories) and haematoxylin were used for staining development and counterstaining, respectively. The primary antibodies used were Hes1 (CST 11988, 1:200), Notch2 (CST 5732, 1:200), GFP (Invitrogen A-11122, 1:400), cleaved caspase-3 (CST 9664, 1:200), Ki-67 (BD Biosciences 550609, 1:200), and Ascl1/Mash1 (BD Biosciences, 556604, 1:200). For staining of allograft and xenograft models treated with tarextumab, tissue sections were stained on a Ventana Discovery Ultra instrument (Roche) using Ventana reagents. Sections were treated with Cell Conditioning 1 before addition of antibodies.
Antibodies were detected with UltraMap HRP kit and ChromoMAP DAB, then counterstained with haematoxylin. Antibodies used were the same as listed above except Ascl1 (eBioscience 1405794) and Ki67 (Abcam ab16667).
For immunofluorescence, paraffin sections were deparaffinized, rehydrated, and unmasked by boiling in Trilogy (Cell Marque 920P-10) for 15 min, then blocked and stained with primary antibodies overnight, or subject to EdU staining (Life Technologies) before blocking and antibody staining. Nuclei were stained with DAPI (Sigma). The following primary antibodies were used: GFP (Rockland 600-101-215, 1:500), Uchl1 (Sigma HPA005993, 1:500), CGRP (Sigma C8198, 1:2,000), synaptophysin (Syp, Neuromics MO20000, 1:100), RFP/Tomato (Rockland 600-401-379, 1:500), phospho-histone H3 (EMD Millipore 06-570, 1:500), and cleaved caspase-3 (CST 9664, 1:100). Quantification of immunostaining. Quantification of all immunostaining was performed blinded. Hes1 pos cells in TKO lung or liver sections or in human tissue microarrays were scored on the basis of the frequency and intensity of Hes1 staining and assigned scores of 0 (no staining), 1 (staining in 1-20% of cells), 2 (staining in 20-60% of cells or strong intense staining in < 20% of cells), or 3 (> 60% staining). Human SCLC tissue microarrays were purchased from US Biomax (LC245, LC802a, LC818), containing a total of 172 cores from 139 patients. H scores were calculated as the summation of (1 + i)p i where i is the intensity score and p i is the percentage of the cells with that intensity.
The frequency of Hes1 pos cells in TKO sections after chemotherapy was quantified from IHC staining using the ImageJ plugin, ImmunoRatio 44 . The percentage of CC3 pos cells in GFP neg or GFP high cells after acute chemotherapy of TKO Hes1 GFP/+ mice was quantified from immunofluorescence images by ImageJ. For studies with human patient-derived xenograft and allograft tumour models performed at OncoMed Pharmaceuticals, slides were scanned using an Aperio AT scanner, then analysed using Definiens Tissue Studio image analysis software. Positively stained cells within tumours were identified and quantitated for staining intensity and frequency. For quantification in Extended Data Fig. 10f -m, some samples were excluded because the paraffin blocks did not have any tissue samples left to be cut (since the tumours were harvested at or close to minimum residual disease, the amount of tissue obtained was small). This exclusion due to unforeseen experimental limitations was not pre-established. Patient survival data. The study was approved by the institutional review board of the East Paris University Hospitals Tumour Bio-bank, AP-HP, Tenon Hospital, Paris, France (AP-HP -GH-HUEP Tumorothèque Bio-bank platform). Seventythree patients diagnosed with SCLC at Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, France, from January 2010 to January 2013 were first identified. Tumour samples were obtained after getting written informed consent. We performed HES1 IHC for 68 of the patients from whom formaldehyde-fixed and paraffin-embedded tumour tissue was available. The tumour samples were first reviewed by at least two independent expert pathologists and the diagnosis of SCLC was histomorphologically confirmed by haematoxylin and eosin staining and IHC for chromogranin A, synaptophysin, NCAM and TTF1. Clinical and biological characteristics of the patients are provided in the Supplementary Methods. For survival analysis, the patients were separated into two groups on the basis of the absence (Hes1-negative) or presence (Hes1-positive) of HES1 immunostaining in their tumours. Luminex assay for midkine protein in human plasma. Human plasma samples from cancer-free normal donors were purchased from BioreclamationIVT. SCLC donor plasma was sourced from Conversant Biologics (Conversant Bio). The samples were collected, processed, and distributed in accordance with institutional review board approval following informed patient consent. Plasma samples were assayed by following the Luminex assay protocol with adaption of the Drop Array system (Curiox Biosystems, Luminex, Austin, Texas, USA). In brief, wells in the DropArray assay plate were blocked with 10 μ l 1% BSA/PBS for 30 min at room temperature. Standards were prepared according to manufacturer's instructions. Bead mix (5 μ l) was added to all wells. Five-microlitre standards or diluted samples were then added to the plate; all standard and human plasma samples were tested in duplicate wells. The plate was shaken for 10 s at 1,000 r.p.m. then placed on a magnetic stand in a humidified chamber and shaken overnight at 4 °C. The plate was washed three times with a DropArray LT washing station MX96 (Curiox Biosystems). The detection antibody was added at 5 μ l per well and the plate was incubated for 60 min. Five microlitres per well of the streptavidin-PE substrate was added to each well and incubated for 30 min with shaking. The plate was washed three times before reading by Luminex 200 instrument. Data were analysed using EMD Millipore's Milliplex Analyst software. The standard curve readings were back-calculated and evaluated for accuracy (80-120%) and precision (percentage coefficient of variation of duplicates < 30%). Immunoblot analysis. Cells were lysed in a modified RIPA buffer (1% NP40, 0.3% SDS, 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% sodium Letter reSeArCH deoxycholate, 30 mM NaF, 20 mM Na 4 P 2 O 7 , 1 mM NaVO 3 , 1 mM DTT, 60 mM β -glycerophosphate) supplemented with protease inhibitors aprotinin (10 μ g ml -1 ), leupeptin (10 μ g ml -1 ), and PMSF (1 mM). Protein concentration was measured with a Pierce BCA protein assay kit (Thermo Scientific). The antibodies used were Notch1 (Cell Signaling Technology (CST) 4380), cleaved Notch1 (CST 4147), Notch2 (CST 5732), Hes1 (CST 11988), GFP (Invitrogen A-11122), Rest (Abcam 21635), alpha-tubulin (Sigma T9026), and HSP90 (CST 4877). DNA and RNA extraction and gene expression analyses. For analysis of primary tumour cells, cells were sorted from pooled tumours from individual TKO Hes1 GFP/+ mice by FACS. DNA and RNA were isolated using a Qiagen Allprep DNA/RNA micro kit or an RNeasy mini kit according to the manufacturer's protocol. qRT-PCR analysis was performed on an Applied Biosystems 7900HT Fast Real-Time PCR System using PerfeCTa SYBR Green FastMix (Quanta BioSciences 95073). Genes having C t values that were high (> 34) or undetermined (for example, Notch4) were removed from the graphical analyses. Data were normalized to Rplp0 as a housekeeping gene, unless otherwise stated. Primer sequences are available in Supplementary Methods. Microarray analysis. RNA from cells isolated by FACS from three TKO Hes1 GFP/+ mice (independent of the samples used for qRT-PCR) was subjected to quality assessment and microarray analysis by the Stanford Protein and Nucleic Acid (PAN) facility as previously described 8 . The microarray was performed using a GeneChip Mouse Gene 2.0 ST Array (Affymetrix), and the Robust Multichip Average (RMA) Express 1.1.0 program was used for background adjustment and quantile RMA normalization of the 41,345 probe sets encoding mouse genome transcripts. Linear models for microarray data (Limma) was used to compare GFP neg and GFP high cells on RMA normalized signal intensities. The command prcomp in R was used for principal component analysis. Probe identifiers were annotated with gene symbols from the mouse gene 2.0 ST transcript cluster database (mogene20sttranscriptcluster.db). Of the 41,345 probe sets, 25,349 were annotated to genes, which were then used for gene set enrichment analysis 45, 46 . Default parameters were used except that we performed gene set permutation instead of phenotype permutation because there were fewer than seven samples per phenotype. Probes with an adjusted P value of 0.05 or less were considered as significantly differentially expressed. Seven thousand and ninety-six probes annotated to 5,437 genes (5,289 unique) were significant, and a heatmap for these genes was generated using the heatmap.2 function in R.
Significantly differentially expressed genes were also analysed by Enrichr 47, 48 . To identify candidate transcription factors that might mediate the NE to non-NE switch, we used genes significantly downregulated in GFP high cells to search for enriched ENCODE and ChEA consensus transcription factors from the ChIP-X database. To identify a list of secreted factors, we first looked at genes that were classified in the 'extracellular space' gene signature and, by literature search, picked out the genes known to be secreted. We also input all significant genes into the ontology search tool in the BIOBASE Knowledge Library 49, 50 , and the output ontologies and gene descriptions were manually screened for secreted factors. We do not exclude the possibility that we might have missed some secreted factors that are not yet well curated in public databases. Candidates for testing in an NE cell growth assay were selected on the basis of expression fold changes and known biology. Single-cell Fluidigm qRT-PCR. Single cells were sorted into individual wells in a 96-well PCR plate containing 5 μ l of 2× reaction mix (CellsDirect One-Step qRT-PCR kit, Invitrogen) with two units of SUPERase In RNase Inhibitor (Thermo Fisher Scientific). Primers were designed and purchased from Fluidigm through the D3 assay design system. Primers were pooled, and reverse transcription and pre-amplification was performed at a final concentration of 50 nM for each primer pair using the following PCR protocol: 15 min at 50 °C, 2 min at 95 °C, 20 cycles of 15 s at 95 °C, and 4 min at 60 °C, 15 min at 4 °C. The complementary DNA (cDNA) products were treated with Exonuclease I (New England Biolabs) to remove unincorporated primers and then diluted fivefold for the final reaction. cDNA (2.25 μ l), 2.5 μ l 2× SsoFast EvaGreen Supermix with low ROX (Bio-Rad 172-5211) and 0.25 μ l 20× DNA Binding Dye sample loading reagent (Fluidigm 100-3738) were mixed and loaded into a 48.48 or 96.96 Dynamic Array integrated fluidic circuit chip. Of each 100 μ M primer pair, 0.25 μ l was mixed with 2.5 μ l 2× Assay Loading reagent (Fluidigm 85000736) and 2.25 μ l TE buffer with low EDTA (Affymetrix 75793) and loaded into the integrated fluidic circuit. The chip was run on a Biomark machine according to the manufacturer's protocol for EvaGreen probes. As established before the experiment, cells with high or undetectable C t values (that is, low expression) for the housekeeping genes (Gapdh, Hsp90ab1, Actb) were excluded from the heatmaps. Genotyping. One nanogram of DNA was used for each multiplex PCR reaction to detect the unrecombined (floxed) and recombined (delta, Δ ) Rb, p53, and p130 alleles. A Rb/p53/p130 (TKO) knockout cell line was a positive control for recombined alleles; DNA isolated from a mouse tail was a negative control. The reverse was true for the unrecombined alleles. Primer sequences are provided in the Supplementary Methods. ChIP. Cells were fixed and ChIP was performed as previously described 51 . In brief, doxycycline-inducible cells were fixed after 48 h of doxycycline treatment. For N1ICD ChIP, KP1-pLIX-N1ICD cells were induced with 0.125 μ g ml -1 of doxycycline and fixed with 2 mM disuccinimidyl glutarate (Thermo Scientific) in PBS for 30 min before formaldehyde fixation. For Rest ChIP, KP1-pLIX-Rest cells were induced with 0.5 μ g ml -1 of doxycycline. The antibodies used were Notch1 (CST 3608), rabbit IgG (CST 2729), and Rest (Millipore 17-641). Primer sequences are provided in the Supplementary Methods. Image analysis and statistics. Sample sizes were chosen on the basis of our experience with similar experiments (a minimum of three to five mice for animal studies, or two to four biological replicates for in vitro/ex vivo assays, usually ensured statistical significance if the phenotypes were robust). Statistical significance was assayed by Student's t-test with GraphPad Prism (two-tailed unpaired or paired t-test, depending on the experiment). * P < 0.05; * * P < 0.01; * * * P < 0.001; * * * * P < 0.0001; NS, not significant. Variance was examined by an F-test. Data are represented as mean ± s.d. unless otherwise stated. For analysis of patient survival data, we used a weighted log-rank test in the OASIS web-based tool 52 with greater emphasis on late time-point differences (rho: 0; gamma: 1). Data availability. Microarray data are available at the NCBI Gene Expression Omnibus under accession number GSE81170. Normalized values for significantly differentially expressed genes are provided in Supplementary Table 1 ; gene set enrichment analyses are in Supplementary Tables 2-4 . HES1 immunostaining and survival data of patients with SCLC are provided in Supplementary Table 5 . 
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Extended Data Figure 5 | Non-neuroendocrine, Notch-active cells in SCLC tumours are generated from neuroendocrine tumour cells. a, Representative IHC for Hes1 and cleaved caspase-3 (CC3) in serial TKO tumour sections. Inset: higher magnification of a positive control for CC3 (tumour from a mouse treated with chemotherapy). b, Predicted numbers and ratios of GFP neg and GFP high tumour cells if the two populations divide independently of each other, and GFP neg cells cycle approximately three times faster than GFP high cells. c, Representative IHC in serial sections from TKO Hes1 GFP/+ tumours initiated by Adeno-CGRP-Cre. d, Quantification of the frequency (Freq.) of Hes1 pos cells in TKO hyperplasias (n = 23, from five mice) and tumours (n = 50, from seven mice) induced by Adeno-CGRP-Cre. Scores: 0 (0%), 1 (1-20%), 2 (20-60%), 3 (> 60%). e, Flow cytometry analysis showing the percentage of GFP high cells in pooled tumours from TKO Hes1 GFP/+ mice (n = 4) infected with Ad-CGRP-Cre. f, Images of freshly isolated GFP neg cells grown on dishes coated with Dll4 or PBS control (representative of n = 3 biological replicates). g, h, Freshly isolated GFP neg cells that remained GFP neg after culture on Dll4-coated dishes were re-plated on dishes coated with Dll4 ligand (+ Dll4) or PBS control (-Dll4). g, Flow cytometry and images (representative of n = 2 biological replicates). h, GFP neg and GFP high cells that formed after this second round of Dll4 stimulation were sorted and analysed by immunoblot. Control: GFP high cell line. i, Relative number of GFP high cells formed from freshly isolated GFP neg cells grown on Dll4 after 2 weeks of tarextumab treatment (n = 3 biological replicates each). j, Single-cell qRT-PCR (n = 45 each) of H29, H82, and H889 human SCLC cell lines. Heatmap was generated by unsupervised clustering of each cell line. Dark blue regions indicate undetectable expression. k, qRT-PCR for HES1 after 72 h of culture with or without Dll4. Data are normalized to GAPDH (n = 3 biological replicates with n = 3 technical replicates each). l, m, GFP high cell lines were treated with DMSO or DBZ while grown with or without Dll4 or co-cultured with three individual NE cell lines in the absence of Dll4. GFP expression was analysed by flow cytometry after 72 h. l, Flow cytometry of GFP high cell line 1 (representative of n = 3 biological replicates; GFP intensity quantified in Fig. 2e ). m, Quantification of GFP intensity in GFP high cell line 2; relative median GFP intensity normalized to the 'DMSO-Dll4' condition (n = 3 biological replicates). n, o, Representative images (n) and qRT-PCR (o) of GFP high cell lines cultured in the presence of absence of Dll4 for more than a month (n = 3 biological replicates with n = 3 technical replicates). p, Freshly isolated GFP neg cells that became GFP high after culture on Dll4 were re-plated on dishes coated with Dll4 ligand or PBS control and analysed by immunoblot after a month. GFP neg cell lysate: positive control for Ascl1. *P < 0.05; **P < 0.01. Statistical significance was determined by two-tailed paired Student's t-test. Data are represented as mean ± s.d. Scale bars, 50 μ m.
